Volume 20 Issue 9
Sep.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(9): 1495-1497
HU Zhou-chao, WANG He-ping, YAN Jin-gang, ZHANG Guo-qiang. Prognostic factors of transarterial chemoembolization combined with radiofrequency ablation for advanced Barcelona clinic liver cancer[J]. Chinese Journal of General Practice, 2022, 20(9): 1495-1497. doi: 10.16766/j.cnki.issn.1674-4152.002632
Citation: HU Zhou-chao, WANG He-ping, YAN Jin-gang, ZHANG Guo-qiang. Prognostic factors of transarterial chemoembolization combined with radiofrequency ablation for advanced Barcelona clinic liver cancer[J]. Chinese Journal of General Practice, 2022, 20(9): 1495-1497. doi: 10.16766/j.cnki.issn.1674-4152.002632
shu

Prognostic factors of transarterial chemoembolization combined with radiofrequency ablation for advanced Barcelona clinic liver cancer

doi: 10.16766/j.cnki.issn.1674-4152.002632
  • 1.

    Interventional Diagnosis and Treatment Center, Affiliated Zhoushan Hospital of Wenzhou Medical University, Zhoushan, Zhejiang 316021, China

Funds:

 LGF21H160020

 2017C31099

  • Received Date: 2021-08-05
    Available Online: 2022-11-29
    Abstract
  •   Objective  To investigate the prognostic factors of the arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of patients with advanced hepatocellular carcinoma (HCC) at Barcelona Clinic stage (BCLC).  Methods  The clinical data of 76 patients with advanced HCC with BCLC who received TACE combined with RFA treatment in our hospital from February 2013 to February 2015 were retrospectively analysed. Kaplan-Meier univariate analysis and Cox multivariate regression were used to analyse the factors affecting overall survival (OS) and progression-free survival (PFS) of patients.  Results  The median OS was 27 months (11 - 68 months), and the median PFS was 15 months (4 - 63 months) in the 76 patients. Kaplan-Meier univariate analysis showed that physical status (PS) score, Child-Pugh grade of liver function, tumour number, tumour diameter, portal vein tumour thrombus, alpha foetal protein, Teggio treatment and times of RFA treatment were closely correlated with median OS (all P < 0.05). Liver function Child-Pugh grade, tumour number, tumour diameter, portal vein tumour thrombus, Teggio treatment and the frequency of RFA treatment were significantly correlated with median PFS (all P < 0.05). Cox multivariate analysis showed that enlargement of tumour diameter and portal vein tumour emboli were independent risk factors for OS and PFS (all P < 0.05), and multiple RFA treatment and Teggio treatment were independent protective factors for PFS (all P < 0.05).  Conclusion  Oral administration of Teggio and increasing the number of RFA treatments are of great help to control the tumour progression in BCLC patients with middle and advanced HCC treated with TACE combined with RFA. However, increase in tumour diameter and portal venous cancer thromboembolism are independent risk factors affecting the prognosis of patients, and corresponding measures should be adopted for clinical prevention and treatment.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    吕天石, 邹英华. 肝癌微创介入治疗进展[J]. 中国临床新医学, 2020, 13(3): 211-215. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYLN202003001.htm

    LYU T S, ZOU Y H. Advances in minimally invasive interventional therapy for hepatocellular carcinoma[J]. Chinese Journal Of New Clinical Medicine, 2020, 13(3): 211-215. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYLN202003001.htm
    [2]
    李少华, 王现兵, 卢昭辉. TACE联合RFA治疗大肝癌的效果及对血清相关指标的影响[J]. 实用癌症杂志, 2020, 35(5): 849-852. doi: 10.3969/j.issn.1001-5930.2020.05.040

    LI S H, WANG X B, LU Z H. Effect of TACE combined with RFA on large hepatocellular carcinoma and its influence on serum related indexes[J]. The Practical Journal of Cancer, 2020, 35(5): 849-852. doi: 10.3969/j.issn.1001-5930.2020.05.040
    [3]
    王艳, 王辉, 游岚岚, 等. 肝动脉化疗栓塞联合射频消融治疗原发性肝癌的临床观察[J]. 实用医院临床杂志, 2017, 14(4): 192-194. https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC201704058.htm

    WANG Y, WANG H, YOU L L, et al. Clinical observation of transcatheter arterial chemoembolization combined with radio frequency ablation in the treatment of primary liver cancer[J]. Practical Journal of Clinical Medicine, 2017, 14(4): 192-194. https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC201704058.htm
    [4]
    高飞, 庞志刚, 韩斌, 等. 肝动脉化疗栓塞联合射频消融术治疗大肝癌的疗效及生存分析[J]. 介入放射学杂志, 2016, 25(4): 316-319. doi: 10.3969/j.issn.1008-794X.2016.04.010

    GAO F, PANG Z G, HAN B, et al. Transcatheter hepatic arterial chemoembolization combined with radiofrequency ablation for large hepatocellular carcinomas: clinical analysis of therapeutic efficacy and survival rate[J]. Journal of Interventional Radiology, 2016, 25(4): 316-319. doi: 10.3969/j.issn.1008-794X.2016.04.010
    [5]
    邓国瑜, 陈洁, 黄山, 等. 基于巴塞罗那分期与香港分期肝细胞肝癌患者不同治疗方案生存率的比较[J]. 肿瘤防治研究, 2019, 46(4): 327-332. doi: 10.3971/j.issn.1000-8578.2019.18.1340

    DENG G Y, CHEN J, HUANG S, et al. Comparison of survival rates based on recommended treatment algorithms of BCLC or HKLC staging systems for hepatocellar carcinoma patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(4): 327-332. doi: 10.3971/j.issn.1000-8578.2019.18.1340
    [6]
    罗小军, 邓和军, 沈艾, 等. 射频消融联合肝动脉化疗栓塞治疗原发性肝癌的临床观察[J]. 中国肿瘤临床与康复, 2016, 23(4): 398-400. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK201604005.htm

    LUO X J, DENG H J, SHEN A, et al. Study of clinical efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization for primary liver cancer[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2016, 23(4): 398-400. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK201604005.htm
    [7]
    黄彦华, 徐锋, 钟丽云. 肝动脉化疗栓塞联合射频消融对肝癌患者细胞免疫功能的影响[J]. 中华全科医学, 2019, 17(9): 1521-1523, 1614. doi: 10.16766/j.cnki.issn.1674-4152.000986

    HUANG Y H, XU F, ZHONG L Y. Effects of transcatheter arterial chemoembolization combined with radiofrequency ablation on cellular immune function in patients with hepatocellular carcinoma[J]. Chinese Journal of General Practice, 2019, 17(9): 1521-1523, 1614. doi: 10.16766/j.cnki.issn.1674-4152.000986
    [8]
    TING W, KUNH Z, PIAO P H, et al. Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases[J]. Oncotarget, 2017, 8(58): 97758-97768.
    [9]
    张浩, 仲富瑞, 程宦立, 等. 肝动脉灌注化疗栓塞联合射频消融治疗中晚期肝癌的疗效分析[J]. 中国普通外科杂志, 2020, 29(1): 35-42. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202001007.htm

    ZHANG H, ZHONG F R, CHENG H L, et al. Efficacy analysis of transcatheter arterial chemoembolization combined with radiofrequency ablation for intermediate and advanced hepatocellular carcinoma[J]. Chinese Journal of General Surgery, 2020, 29(1): 35-42. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202001007.htm
    [10]
    周固超. 肝细胞性肝癌根治术后预后因素分析[D]. 芜湖: 皖南医学院, 2019.

    ZHOU G C. Prognostic factors of hepatocellular carcinoma after radical resection[D]. Wuhu: Wannan Medical College, 2019.
    [11]
    刘礼军, 余伟. 微创介入手术对原发性肝癌患者疗效及预后的影响研究[J]. 中国肿瘤临床与康复, 2018, 25(6): 705-707. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK201806020.htm

    LIU L J, YU W. Effect of minimally invasive intervention on efficacy and prognostis in patients with primary hepatocellular carcinoma[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2018, 25(6): 705-707. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK201806020.htm
    [12]
    梁寻杰, 覃小珊, 黄赞松. 肝癌预后影响因素研究进展[J]. 右江民族医学院学报, 2020, 42(5): 642-645. https://www.cnki.com.cn/Article/CJFDTOTAL-YJMZ202005026.htm

    LIANG X J, TAN X S, HUANG Z S. Research progress on prognostic factors of hepatocellular carcinoma[J]. Journal of Youjiang Medical University for Nationalities, 2020, 42(5): 642-645. https://www.cnki.com.cn/Article/CJFDTOTAL-YJMZ202005026.htm
    [13]
    黄海, 竺越, 保志军, 等. 肝动脉化疗栓塞术治疗老年肝癌病人的疗效及预后影响因素分析[J]. 实用老年医学, 2019, 33(6): 577-581. https://www.cnki.com.cn/Article/CJFDTOTAL-SYLA201906016.htm

    HUANG H, ZHU Y, BAO Z J, et al. Prognostic factors of elderly patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization[J]. Practical Geriatrics, 2019, 33(6): 577-581. https://www.cnki.com.cn/Article/CJFDTOTAL-SYLA201906016.htm
    [14]
    刘娜娜, 钱贤峰. 肝动脉化疗栓塞联合射频消融术治疗原发性肝癌效果分析[J]. 医学理论与实践, 2020, 33(24): 4104-4106.

    LIU N N, QIAN X F. Efficacy of transcatheter arterial chemoembolization combined with radiofrequency ablation for primary hepatocellular carcinoma[J]. The Journal of Medical Theory and Practice, 2020, 33(24): 4104-4106.
    [15]
    李一帆, 顾俊鹏, 纪卫政, 等. TACE联合RFA治疗BCLC中晚期肝癌患者预后的影响因素分析[J]. 中华肝脏外科手术学电子杂志, 2020, 9(6): 557-561.

    LI Y F, GU J P, JI W Z, et al. Prognostic factors of primary liver cancer patients in BCLC intermediate and advanced stage after TACE combined with RFA[J]. Chinese Journal of Hepatic Surgery (Electronic Edition), 2020, 9(6): 557-561.
    [16]
    毕丽华. 替吉奥或紫杉醇联合索拉非尼治疗原发性肝癌的预后对比分析[J]. 解放军预防医学杂志, 2018, 36(5): 647-649. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYX201805026.htm

    BI L H. Prognosis of liver cancer treated with Tegafur or Paclitaxel combined with Sorafenib[J]. Journal of Preventive Medicine of Chinese People' s Liberation Army, 2018, 36(5): 647-649. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYX201805026.htm
    [17]
    蒋长晨, 朱锡旭, 丁涤非, 等. 替吉奥联合TACE治疗BCLC B期原发性肝癌疗效分析[J]. 现代肿瘤医学, 2017, 25(22): 3660-3664. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL201722029.htm

    JIANG C C, ZHU X X, DING D F, et al. Efficacy of TACE in combination with oral S-1 in patients with BCLC B stage hepatocellular carcinoma[J]. Journal of Modern Oncology, 2017, 25(22): 3660-3664. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL201722029.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (261) PDF downloads(1) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return